Silydianin

Pharmacology & Research

Silydianin is the fourth flavonolignan of the silymarin complex from milk thistle seed — a minor sibling (~5–10%) of the dominant silybin (silibinin), isosilybin and silychristin. Its distinctive feature is structural, not pharmacological: unlike the others it has an unusual bicyclic skeleton (a keto group adjacent to a hemiacetal) rather than the typical benzodioxane-type linkage — the “odd one out” of the group. Its own literature is genuinely scant, and as with the other congeners, milk thistle’s clinical evidence rests on the silymarin complex/silibinin, not isolated silydianin.

1. Antioxidant / radical scavenging

In DPPH ranking, the order was silymarin > silychristin > silydianin > silybin — so silydianin is an intermediate scavenger, stronger than silybin but weaker than silychristin ^{2Reference 2Sersen F et al. · 2006Silymarin and its components scavenge phenylglyoxylic ketyl radicalsView study →}, and a review places the non-silybin congeners (silydianin included) as potentially better antioxidants than the headline silybin ^{1Reference 1Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}. (Note: the common assumption that silydianin is the weakest of the group does not hold — silybin usually is.)

Gap: in-vitro chemistry only, with no cellular-outcome or human antioxidant-endpoint data for the isolate ^{2Reference 2Sersen F et al. · 2006Silymarin and its components scavenge phenylglyoxylic ketyl radicalsView study →}.

2. Hepatoprotective / cytoprotective

Silydianin contributes to the silymarin complex’s cytoprotection — for example against anthracycline toxicity in cardiomyocytes ^{6Reference 6Chlopčíková Š et al. · 2004AnimalChemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes: silymarin and its flavonolignansView study →} and in the skin-protective (UV/oxidative) activity of the flavonolignan set ^{5Reference 5Vostálová J et al. · 2019Skin-protective activity of silymarin and its flavonolignansView study →}.

Gap: the actual hepatoprotective clinical evidence belongs to silymarin/silibinin and must not be transferred to this isolate ^{1Reference 1Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}.

3. Bone / osteogenic

Silymarin enhanced alkaline phosphatase and osteocalcin in osteoblasts and improved fracture healing in mice ^{3Reference 3Kim JL et al. · 2012AnimalOsteogenic activity of silymarin through enhancement of alkaline phosphatase and osteocalcin in osteoblasts and tibia-fractured miceView study →}, and the congener silibinin promotes osteoblastogenesis while suppressing osteoclast differentiation ^{4Reference 4Kim JL et al. · 2012Osteoblastogenesis and osteoprotection enhanced by the flavonolignan silibinin in osteoblasts and osteoclastsView study →}.

Gap: this is complex-/silibinin-level, with no silydianin-specific bone study — honest class context only ^{3,4Reference 3Kim JL et al. · 2012AnimalOsteogenic activity of silymarin through enhancement of alkaline phosphatase and osteocalcin in osteoblasts and tibia-fractured miceView study →Reference 4Kim JL et al. · 2012Osteoblastogenesis and osteoprotection enhanced by the flavonolignan silibinin in osteoblasts and osteoclastsView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Free radicals (DPPH, ketyl)	direct scavenging, moderate (> silybin, < silychristin)	antioxidant
Nrf2 / antioxidant-response (class-level)	proposed cytoprotective-gene induction (inferred, not isolate-proven)	antioxidant, cytoprotective
Osteoblast markers (ALP, osteocalcin; class-level)	enhanced for silymarin/silibinin, not silydianin specifically	bone (exploratory)

Pharmacokinetics

Silydianin shares the flavonolignan class’s poor aqueous solubility and poor oral bioavailability — the seed complex is not water-soluble, so teas do not deliver a meaningful dose, and standardised extracts or phospholipid complexes are used for the parent complex ^{1Reference 1Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}. No dedicated human pharmacokinetic study of the isolate exists, so low systemic exposure from oral intake should be assumed, and silydianin’s distinctive reactive bicyclic structure also makes it comparatively chemically labile.

Clinical trials

There are no trials of isolated silydianin. All human evidence tied to milk thistle is on the silymarin complex or silibinin/silybin (NAFLD, chronic liver disease, IV Legalon SIL for Amanita poisoning) — not this single molecule.

Last checked: July 2026.

Toxicity & Safety

Silydianin has a [low] toxicity verdict — no signal of intrinsic toxicity, and it reaches humans normally only as a minor (~5–10%) fraction of a well-tolerated seed extract. Unlike its sibling silychristin it carries no distinctive target-based caveat (no MCT8 activity reported), and Asteraceae-allergy caution applies to milk-thistle products generally.

Pregnancy & lactation

Precautionary — avoid the isolate. No pregnancy or lactation data exist for concentrated isolated silydianin; with no human safety data on the purified molecule, avoid the isolate (standardised silymarin as a normal dietary/supplemental extract is a separate question handled on the complex page).

Dosage

There is no established therapeutic dose — silydianin is not sold or dosed as an isolate and is consumed only as ~5–10% of a standardised silymarin extract, so any figure would be extrapolation from the complex.

References